HEALTHCARE TODAY
  • IN THE SPOTLIGHT
  • DIGITAL HEALTH
  • PRODUCTS & SUPPLEMENTS
  • HEALTH A - Z
  • PARENTING
  • MEN'S HEALTH
  • WOMEN
  • AGEING
  • NUTRITION
  • FITNESS
  • COMPLIMENTARY MEDICINE
  • ABOUT US
  • IN THE SPOTLIGHT
  • DIGITAL HEALTH
  • PRODUCTS & SUPPLEMENTS
  • HEALTH A - Z
  • PARENTING
  • MEN'S HEALTH
  • WOMEN
  • AGEING
  • NUTRITION
  • FITNESS
  • COMPLIMENTARY MEDICINE
  • ABOUT US
Search

ROCHE LAUNCHES PERJETA - HERCEPTIN COMBINATION, A POST-SURGERY TREATMENT FOR EARLY BREAST CANCER (eBC)

MARCH 8, 2019 @9 PM
Picture
(Left to right) Dr Ng Char Hong, Lance Duan, Dr Matin Mellor at the official launch of Perjeta - Herceptin combination.
Roche (Malaysia) Sdn Bhd today launched Perjeta (pertuzumab), approved in Malaysia for use in combination with Herceptin (trastuzumab) and chemotherapy for the adjuvant treatment (post-surgery) of patients with HER2-positive early breast cancer at high risk of recurrence. 

Breast cancer is the most common cancer among women globally. Every 15 seconds, one woman is diagnosed with breast cancer somewhere in the world. Breast cancer is the most common form of malignancy affecting women and the disease burden of breast cancer affects 32.1% of all women living with cancer in Malaysia. 

Human Epidermal Growth Factor Receptor 2 (HER2)
The over-expression of Human Epidermal Growth Factor Receptor 2 (HER2) is associated with poor prognosis which results in shortened time to relapse and shorter overall survival in patients. Studies showed that 23%-28% of patients diagnosed with breast cancer are HER2-positive breast cancer in Malaysia. 

“HER2-positive eBC is an aggressive disease, and additional risk factors, such as lymph node involvement will lead certain patients to experience disease recurrence even earlier. Despite adjuvant treatment with trastuzumab, approximately one in four HER2-positive early Breast Cancer women experience a relapse of their disease in the long-term,” said Dr Matin Mellor, Consultant Clinical Oncologist at the official launch event of Perjeta - Herceptin combination. 

Adding to his comment, Dr Ng Char Hong, Consultant Breast and Breast Reconstructive Surgeon said that the only setting where HER2-positive breast cancer can potentially be cured is at the early stage.

"There is no cure for breast cancer that recurs and reaches an advanced stage where treatment is solely aimed at prolonging life for as long as possible. Thus, it is clinically meaningful to effectively treat breast cancer patients at the earliest stage.”

Previously, the combination (Perjeta + Herceptin + Chemotherapy) was approved for the treatment of metastatic HER2-positive breast cancer, where it has been shown to significantly extend survival compared to Herceptin and chemotherapy alone. Now, with the adjuvant approval, it means that eligible patients with HER2-positive eBC in Malaysia could be treated with the Perjeta - Herceptin combination for a total of one year as part of a complete regimen for eBC.

Perjeta
Perjeta targets the HER2 receptor, a protein found on the surface of many normal cells and in high quantities on the surface of cancer cells in HER2-positive cancers. It is designed specifically to prevent the HER2 receptor from pairing (or ‘dimerising’) with other HER receptors (EGFR/HER1, HER3 and HER4) on the surface of cells.  

The mechanisms of action of Perjeta and Herceptin are believed to complement each other. Both bind to the HER2 receptor but to different places. The combination is thought to provide a more comprehensive, dual blockade of HER signalling pathways, thus preventing tumour cell growth and survival.

Clinical trial 
A Phase 3 clinical trial (APHINITY) involving over 4,800 people with HER2-positive eBC was conducted. In summary, APHINITY showed that adding Perjeta to Herceptin and chemotherapy after surgery reduced the risk of invasive breast cancer recurrence or death (invasive disease-free survival; iDFS) compared to Herceptin and chemotherapy alone in the overall study population.

The greatest benefit in the trial was observed in patients with lymph node-positive or hormone receptor-negative breast cancer: 

• For patients with lymph node-positive disease, the combination reduced the risk of recurrence or death by 23%.
• Among patients with hormone receptor-negative disease, the combination reduced the risk of recurrence or death by 24%.

In terms of the safety profile of Perjeta - Herceptin combination, it is consistent as reported previously, with low incidence of primary cardiac events (<1%) and no new safety issued noted. 

“Roche’s treatment goal for early breast cancer is to cure the disease. While treatment outcomes have improved over the years, unfortunately, some patients still have recurrence of breast cancer. As such, today’s launch of Perjeta - Herceptin combination as an adjuvant treatment is highly significant. There is another option that can make an even greater contribution to the advancement of breast cancer treatment,” shared Lance Duan, Managing Director, Roche (Malaysia) Sdn Bhd. 

Roche's Patient Assistance Programme
Perjeta - Herceptin combination has also been included in MY Roche’s Patient Assistance Programme which is committed to helping eligible patients access the Roche medicines they are prescribed. Under the programme, the subsidised medications will benefit the patients in supporting their overall treatment cost.

For further information on Perjeta - Herceptin combination and MY Roche’s Patient Assistance Programme, please contact your oncologist, or treating physician.
 
PERJETA- HERCEPTIN Combination is now approved in more than 70 countries for adjuvant therapy for HER2-positive early breast cancer, including in the United States, Europe, Japan, Canada and a few ASEAN countries like Singapore, Thailand and Philippines.
RECOMMENDED
Picture
​Shield your eyes from harmful blue light with Brand's Lutein Essence

Picture
​Keytruda with chemotherapy to be the first line of treatment for patients with advanced lung cancer

​Tumour profiling for personalised cancer therapy
Picture
​​Tune Protect launch extreme sports plan

AIA unveils A-Plus health plan
Coca-cola rolls out Nutri Boost
Diapo-care cream for diaper rash
Repatha to reduce bad cholesterol
Pantai improves detection of eye diseases with OCT Technology
Sensodyne Rapid Relief helps ease tooth sensitivity
TOP STORIES
Picture
​Prince Court Medical Centre launch Intraoperative Radiotherapy for breast cancer treatment

Picture
​Blue Socks creates awareness on diabetic peripheral neuropathy

Picture
​PM Tun Mahathir launch MySalam scheme to aid B40s with critical illness and hospitalisation

Picture
Self-sampling HPV test to eliminate cervical cancer in Malaysia

Picture
​Survey reveals mental health and stress continue to affect organisation's bottom line
​Teacher's battle against pregnancy discrimination recognised with human rights award
15 companies win Malaysia's healthiest workplace awards
Malaysia ranks seventh in the world with highest number of dialysis treatment rate
Mimos to roll-out first clinically-tested non-invasive glucose monitor end of 2019
Sarawak General Hospital joins QVIA's network of globally qualified phase 1 oncology sites
Cardiac care for the economically challenged
HEALTH A - Z
Picture
​Are you in a physical - psychological abusive relationship?

Domestic violence can affect children even before they’re born
When mental illness is mistaken for demonic possession
Eating disorders - A mental health issue
How mental health affects your life
Schizophrenia: Living in a world that does not exist
Picture
Are you sad or depressed? How do you differentiate the two?
Picture
The psychology behind public masturbation and indecent exposure
Domestic violence and abuse - The impact on children and adolescents
Arson, animal cruelty and lack of remorse - traits of personality disorders to look out for in a person
CHILDREN
Picture
​Malaysia's butterfly children with skin as fragile as a butterfly wings
Picture
Is it bad to co-sleep with your baby?

MEN'S HEALTH
Have trouble peeing?
Picture
Does spicy food affect your prostate health?

Picture
​Cigarettes cause bladder cancer
Picture

IN THE SPOTLIGHT

HEALTH A - Z

MEN'S HEALTH

AGEING

NUTRITION

ABOUT US

PRODUCTS & SUPPLEMENTS

PARENTING

WOMEN

FITNESS

​COMPLIMENTARY MEDICINE

BM
​Copyright@ 2018 Healthcare Today. All rights reserved. The material in this site is intended to be of general information use and is not intended to constitute medical
advice, probable diagnosis or recommended treatments.                                                              
  • IN THE SPOTLIGHT
  • DIGITAL HEALTH
  • PRODUCTS & SUPPLEMENTS
  • HEALTH A - Z
  • PARENTING
  • MEN'S HEALTH
  • WOMEN
  • AGEING
  • NUTRITION
  • FITNESS
  • COMPLIMENTARY MEDICINE
  • ABOUT US